When is it time to have your joint checked?

Which warning signs need prompt care?

Seek prompt medical care for a joint that is hot, red, and swollen with fever or chills. Get quick care if an injured joint looks misshapen or can't bear your weight. Don't wait with those signs.

New numbness or weakness needs prompt help, especially with lost bladder control or bowel control. A knee locked by an injury deserves quick attention as well. These problems need urgent medical care, not a routine clinic appointment.

When is a regular visit worthwhile?

A regular visit makes sense when the ache keeps returning or wakes you. It's also worthwhile when soreness cuts short walking, dressing, or another daily task. An exam can find the tender area and check the joint's movement.

Before the visit, ask your doctor's office for a copy of any earlier X-ray or scan report, and note the date or activity that first brought on the ache. A written list of the medicines you take will help. That small bit of planning helps.

What happens during the visit?

A medical provider, the clinic staff member who examines joints, will ask how the soreness started. You'll be asked which movements hurt and what you now avoid. The provider will also check how the joint moves.

You may ask what each choice is made from and what relief is realistic. Request a complete written price that includes the visit and later care. While you wait, keep to gentle motion that feels safe.

You don't have to agree to care at the first visit. Take time to think about the answers and speak with your own doctor. QC Kinetix starts with a consultation and may offer regenerative treatment options, meaning non-surgical care intended to help the joint repair itself.

Sources

1. The AAOS third-edition clinical practice guideline for non-arthroplasty management of knee osteoarthritis is the orthopedic profession's own GRADE-style appraisal of the same options a regenerative clinic sells; it is the benchmark against which any 'regenerative' claim on this topic should be read, and it rates the strongest support for exercise, weight loss and self-management rather than for injectables.

   Brophy RH, et al. — AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition.. The Journal of the American Academy of Orthopaedic Surgeons, 2022. DOI: 10.5435/JAAOS-D-21-01233.

2. The Cochrane review of exercise for knee osteoarthritis found high-quality evidence that land-based therapeutic exercise provides short-term benefit in pain and physical function, sustained for at least 2-6 months after the programme ends, with mild transient soreness the only reported adverse effect across 45 trials. It is the best-evidenced treatment for this condition and it costs nothing per injection.

   Fransen M, et al. — Exercise for osteoarthritis of the knee.. The Cochrane database of systematic reviews, 2015. DOI: 10.1002/14651858.CD004376.pub3.

3. A GRADE-rated systematic review and meta-analysis of 16 randomized trials (807 participants) found that MSC therapy for chronic knee OA pain PROBABLY RESULTS IN LITTLE TO NO DIFFERENCE in pain relief at 3-6 months (WMD -0.74 cm on a 10 cm VAS against a minimally important difference of 1.5 cm) or physical functioning (WMD 2.23 on the SF-36 100-point subscale against a 10-point MID), both moderate certainty; at 12 months pain was again probably little-to-no-different (WMD -0.73 cm). The measured effect is real but sits BELOW the threshold at which a patient would notice it.

   Sadeghirad B, et al. — Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials.. Osteoarthritis and cartilage, 2024. DOI: 10.1016/j.joca.2024.04.021.

4. The AAOS clinical practice guideline summary on SURGICAL management of knee osteoarthritis - the other end of the ladder, and the honest comparator for anyone told a biologic injection will let them avoid an operation.

   Srivastava AK, et al. — American Academy of Orthopaedic Surgeons Clinical Practice Guideline Summary of Surgical Management of Osteoarthritis of the Knee.. The Journal of the American Academy of Orthopaedic Surgeons, 2023. DOI: 10.5435/JAAOS-D-23-00338.

5. A systematic review of the discordance between clinical and radiographic knee osteoarthritis: many people with severe-looking x-rays have little pain, and many with disabling pain have modest radiographic change. This is the reason a post-treatment scan is a poor proxy for how someone feels, in either direction.

   Bedson J, et al. — The discordance between clinical and radiographic knee osteoarthritis: a systematic search and summary of the literature.. BMC musculoskeletal disorders, 2008. DOI: 10.1186/1471-2474-9-116.

6. The RESTORE trial - a participant-, injector- and assessor-blinded RCT of 288 adults aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence 2-3) - compared three weekly intra-articular PRP injections against saline placebo, with co-primary endpoints of 12-month knee pain and medial tibial cartilage volume on MRI. PRP did not beat placebo on either. It is the single best-designed test of the specific claim that PRP changes joint structure, and it was negative.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

7. A four-arm, multicentre, single-blind phase 2/3 randomized trial of 480 knee OA patients (KL II-IV) compared autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic umbilical-cord-tissue mesenchymal stromal cells against a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another, or to the corticosteroid control, and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events occurred.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature medicine, 2023. DOI: 10.1038/s41591-023-02632-w.

8. FDA states plainly that no stem cell, exosome, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic-fluid product has been approved for the treatment of ANY orthopedic condition - it names osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain individually. The only FDA-approved stem cell products in the United States are cord-blood-derived blood-forming stem cells for disorders of the hematopoietic system, and there are currently no FDA-approved exosome products.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA, 2020.